- Home
- BRT vs IPSC Comparison
BRT vs IPSC Comparison
Compare BRT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | IPSC |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 248.1M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRT | IPSC |
|---|---|---|
| Price | $13.36 | $1.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $18.00 | $4.75 |
| AVG Volume (30 Days) | 57.2K | ★ 727.5K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | $97,028,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $1.10 | N/A |
| Revenue Next Year | $7.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 1556.76 |
| 52 Week Low | $13.13 | $0.44 |
| 52 Week High | $15.63 | $2.97 |
Technical Indicators
Market Signals| Indicator | BRT | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 40.01 |
| Support Level | $13.18 | $1.22 |
| Resistance Level | $14.87 | $2.45 |
| Average True Range (ATR) | 0.28 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 45.90 | 43.11 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.